

Experiment Number: 20601 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 03/08/2016

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

F2_M3

NTP Study Number: C20601
Lock Date: 06/22/2011
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.3_002
PWG Approval Date: 12/09/2014

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	60	60	60
Scheduled Sacrifice	10	10	10	10
Early Deaths				
Accidentally Killed		1		
Moribund Sacrifice	7	12	15	26
Natural Death	5	7	8	7
Survivors				
Terminal Sacrifice	38	30	27	17
Animals Examined Microscopically	60	60	60	60

ALIMENTARY SYSTEM

Esophagus	(60)	(60)	(60)	(60)
Hepatocolangiocarcinoma, Metastatic, Liver	1 (2%)			
Gallbladder	(52)	(51)	(47)	(49)
Intestine Large, Cecum	(56)	(55)	(55)	(57)
Adenoma		2 (4%)		
Intestine Large, Colon	(58)	(55)	(57)	(58)
Intestine Large, Rectum	(57)	(52)	(55)	(58)
Intestine Small, Duodenum	(55)	(55)	(52)	(56)
Adenoma	2 (4%)			
Intestine Small, Ileum	(56)	(54)	(53)	(58)
Adenoma			1 (2%)	
Intestine Small, Jejunum	(56)	(54)	(52)	(58)
Carcinoma	1 (2%)	1 (2%)		1 (2%)
Liver	(60)	(60)	(59)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Cholangiocarcinoma	1 (2%)			
Cholangioma				1 (2%)
Hemangiosarcoma				1 (2%)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Hepatoblastoma	2 (3%)	1 (2%)		4 (7%)
Hepatocellular Adenoma	14 (23%)	17 (28%)	23 (39%)	18 (30%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hepatocellular Adenoma, Multiple	19 (32%)	16 (27%)	16 (27%)	20 (33%)
Hepatocellular Carcinoma	14 (23%)	18 (30%)	8 (14%)	17 (28%)
Hepatocellular Carcinoma, Multiple	2 (3%)	6 (10%)	7 (12%)	5 (8%)
Hepatocholangiocarcinoma	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Mesentery	(7)	(4)	(4)	(6)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (14%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (25%)		
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(59)	(59)	(59)	(60)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Salivary Glands	(60)	(60)	(60)	(60)
Stomach, Forestomach	(60)	(60)	(59)	(60)
Squamous Cell Papilloma	1 (2%)			
Stomach, Glandular	(58)	(58)	(59)	(60)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Tooth	(15)	(14)	(14)	(6)

CARDIOVASCULAR SYSTEM

Blood Vessel	(60)	(59)	(58)	(54)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Heart	(60)	(60)	(60)	(60)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	2 (3%)
Hemangioma		1 (2%)		
Hemangiosarcoma			2 (3%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Epicardium, Carcinoma, Metastatic, Uncertain Primary Site		1 (2%)	1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(59)	(60)	(59)	(59)
Adenoma		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Capsule, Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Subcapsular, Adenoma	4 (7%)		2 (3%)	
Zona Fasciculata, Adenoma			1 (2%)	
Adrenal Medulla	(59)	(60)	(56)	(59)
Pheochromocytoma Benign			1 (2%)	
Islets, Pancreatic	(59)	(59)	(59)	(60)
Adenoma			1 (2%)	
Parathyroid Gland	(33)	(39)	(31)	(41)
Pituitary Gland	(59)	(59)	(58)	(59)
Pars Distalis, Adenoma			2 (3%)	
Thyroid Gland	(59)	(59)	(58)	(59)
C-cell, Carcinoma		1 (2%)		
Follicular Cell, Adenoma			1 (2%)	
Follicular Cell, Carcinoma			1 (2%)	

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
------------	-----	-----	-----	-----

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)
GENITAL SYSTEM				
Epididymis	(60)	(60)	(60)	(60)
Fibrosarcoma			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Preputial Gland	(60)	(60)	(59)	(60)
Prostate	(59)	(60)	(59)	(60)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Seminal Vesicle	(59)	(60)	(59)	(60)
Adenoma	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Testes	(59)	(59)	(60)	(60)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(59)	(60)	(58)	(60)
Hemangiosarcoma, Metastatic, Lymph Node		1 (2%)		
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Lymph Node	(2)	(2)	(2)	(2)
Hemangiosarcoma		1 (50%)		
Iliac, Hemangiosarcoma			1 (50%)	
Pancreatic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (50%)
Lymph Node, Bronchial	(38)	(53)	(57)	(51)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		3 (6%)	1 (2%)	5 (10%)
Hemangiosarcoma, Metastatic, Heart			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hepatocellular Carcinoma, Metastatic, Liver	1 (3%)			1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (3%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Lymph Node, Mandibular	(32)	(30)	(32)	(30)
Lymph Node, Mediastinal	(41)	(53)	(58)	(59)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	3 (5%)	4 (7%)
Carcinoma, Metastatic, Uncertain Primary Site			1 (2%)	
Hemangiosarcoma, Metastatic, Heart			1 (2%)	
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			2 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Lymph Node, Mesenteric	(58)	(57)	(57)	(60)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Spleen	(59)	(60)	(60)	(60)
Hemangiosarcoma	2 (3%)		1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant		1 (2%)		
Thymus	(51)	(48)	(53)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)		3 (6%)
Hemangiosarcoma, Metastatic, Heart			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
INTEGUMENTARY SYSTEM				
Mammary Gland	(0)	(2)	(4)	(1)
Skin	(60)	(60)	(60)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Fibrosarcoma			2 (3%)	
Fibrous Histiocytoma		1 (2%)	1 (2%)	4 (7%)
Hemangioma		1 (2%)		
Sebaceous Gland, Carcinoma			1 (2%)	
Subcutaneous Tissue, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(60)	(60)	(59)	(60)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Skeletal Muscle	(2)	(3)	(1)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (50%)			
Rhabdomyosarcoma		1 (33%)		
NERVOUS SYSTEM				
Brain	(60)	(60)	(60)	(60)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Peripheral Nerve	(1)	(1)	(0)	(0)
Spinal Cord	(1)	(2)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
RESPIRATORY SYSTEM				
Larynx	(60)	(60)	(60)	(60)
Lung	(60)	(60)	(60)	(60)
Alveolar/Bronchiolar Adenoma	7 (12%)	11 (18%)	9 (15%)	10 (17%)
Alveolar/Bronchiolar Adenoma, Multiple	3 (5%)	3 (5%)	2 (3%)	4 (7%)
Alveolar/Bronchiolar Carcinoma	4 (7%)	13 (22%)	15 (25%)	18 (30%)
Alveolar/Bronchiolar Carcinoma, Multiple		5 (8%)	6 (10%)	11 (18%)
Hepatoblastoma, Metastatic, Liver	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	3 (5%)	2 (3%)	5 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Nose	(60)	(59)	(59)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Pleura	(0)	(0)	(0)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (50%)
Trachea	(59)	(60)	(60)	(60)

SPECIAL SENSES SYSTEM

Eye	(58)	(59)	(57)	(60)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Retrolbulbar, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Harderian Gland	(59)	(60)	(60)	(60)
Adenoma	5 (8%)	5 (8%)	4 (7%)	3 (5%)
Adenoma, Multiple	1 (2%)	1 (2%)		
Carcinoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hemangioma				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

URINARY SYSTEM

Kidney	(60)	(60)	(59)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)		1 (2%)	1 (2%)
Plasma Cell Tumor Malignant		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Ureter	(1)	(0)	(0)	(0)
Urinary Bladder	(60)	(60)	(58)	(60)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		

SYSTEMIC LESIONS

Multiple Organ	*(60)	*(60)	*(60)	*(60)
Histiocytic Sarcoma	1 (2%)	1 (2%)	3 (5%)	1 (2%)
Lymphoma Malignant	4 (7%)	4 (7%)	3 (5%)	6 (10%)
Mesothelioma Malignant				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	48	48	53	52
Total Primary Neoplasms	90	114	116	127
Total Animals with Benign Neoplasms	40	40	43	42
Total Benign Neoplasms	57	58	63	57
Total Animals with Malignant Neoplasms	26	41	38	44
Total Malignant Neoplasms	33	56	53	70
Total Animals with Metastatic Neoplasms	5	9	11	14
Total Metastatic Neoplasms	20	38	24	37
Total Animals with Malignant Neoplasms Uncertain Primary Site		1	3	
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	60	60	60
Scheduled Sacrifice	10	10	10	10
Early Deaths				
Accidentally Killed	1			
Moribund Sacrifice	10	11	16	27
Natural Death	3	8	8	8
Survivors				
Terminal Sacrifice	36	31	26	15
Animals Examined Microscopically	60	60	60	60

ALIMENTARY SYSTEM

Esophagus	(60)	(60)	(60)	(60)
Gallbladder	(56)	(51)	(54)	(55)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Intestine Large, Cecum	(57)	(54)	(58)	(57)
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Polyp Adenomatous				1 (2%)
Intestine Large, Colon	(57)	(57)	(59)	(57)
Intestine Large, Rectum	(54)	(56)	(58)	(57)
Intestine Small, Duodenum	(57)	(54)	(55)	(55)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Intestine Small, Ileum	(57)	(55)	(57)	(55)
Hemangiosarcoma		1 (2%)		
Intestine Small, Jejunum	(57)	(53)	(56)	(54)
Adenoma			1 (2%)	1 (2%)
Carcinoma		1 (2%)		
Liver	(60)	(60)	(60)	(60)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hemangioma			1 (2%)	
Hemangiosarcoma			1 (2%)	
Hepatocellular Adenoma	9 (15%)	11 (18%)	13 (22%)	19 (32%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hepatocellular Adenoma, Multiple	2 (3%)	5 (8%)	5 (8%)	2 (3%)
Hepatocellular Carcinoma	4 (7%)	10 (17%)	9 (15%)	3 (5%)
Hepatocellular Carcinoma, Multiple	2 (3%)	1 (2%)	3 (5%)	1 (2%)
Hepatocholangiocarcinoma	1 (2%)	2 (3%)		
Mesentery	(9)	(12)	(16)	(7)
Fibrosarcoma, Metastatic, Pancreas		1 (8%)		
Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (6%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (8%)		
Lipoma	1 (11%)			
Pancreas	(60)	(60)	(60)	(60)
Fibrosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Liver			1 (2%)	
Salivary Glands	(60)	(60)	(60)	(60)
Myxosarcoma	1 (2%)			
Stomach, Forestomach	(60)	(60)	(60)	(60)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Squamous Cell Papilloma	1 (2%)			
Stomach, Glandular	(60)	(59)	(60)	(60)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Tongue	(0)	(1)	(0)	(0)
Tooth	(1)	(2)	(2)	(1)

CARDIOVASCULAR SYSTEM

Blood Vessel	(60)	(57)	(57)	(56)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Heart	(60)	(60)	(60)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)	1 (2%)	1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
ENDOCRINE SYSTEM				
Adrenal Cortex	(60)	(60)	(60)	(60)
Adenoma		1 (2%)		
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Capsule, Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Capsule, Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Subcapsular, Adenoma	1 (2%)		1 (2%)	
Adrenal Medulla	(60)	(60)	(58)	(59)
Pheochromocytoma Benign		2 (3%)		3 (5%)
Pheochromocytoma Malignant				1 (2%)
Islets, Pancreatic	(60)	(59)	(59)	(59)
Adenoma		1 (2%)	1 (2%)	1 (2%)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Parathyroid Gland	(35)	(42)	(40)	(40)
Adenoma				1 (3%)
Pituitary Gland	(59)	(60)	(60)	(60)
Pars Distalis, Adenoma	9 (15%)	10 (17%)	7 (12%)	3 (5%)
Pars Distalis, Carcinoma			1 (2%)	
Pars Intermedia, Adenoma		1 (2%)	1 (2%)	
Thyroid Gland	(58)	(59)	(60)	(60)
Follicular Cell, Adenoma				1 (2%)
Follicular Cell, Carcinoma			1 (2%)	
GENERAL BODY SYSTEM				
Peritoneum	(0)	(0)	(1)	(0)
GENITAL SYSTEM				
Clitoral Gland	(58)	(53)	(54)	(49)
Ovary	(60)	(59)	(60)	(60)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Cystadenoma	1 (2%)	2 (3%)	2 (3%)	
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Granulosa Cell Tumor Malignant	1 (2%)		1 (2%)	
Granulosa-Theca Tumor Malignant		1 (2%)		
Hemangioma		1 (2%)		1 (2%)
Hemangiosarcoma	1 (2%)		1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Luteoma		2 (3%)		
Oviduct	(1)	(0)	(0)	(0)
Uterus	(60)	(60)	(60)	(60)
Carcinoma			1 (2%)	
Granular Cell Tumor Benign	1 (2%)			
Hemangiosarcoma	1 (2%)		1 (2%)	
Leiomyoma		2 (3%)		
Polyp Stromal	4 (7%)	2 (3%)	1 (2%)	2 (3%)
Endometrium, Polyp Stromal				1 (2%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(60)	(60)	(60)	(60)
Mast Cell Tumor Nos, Metastatic, Uncertain Primary Site				1 (2%)
Lymph Node	(6)	(9)	(14)	(16)
Hemangioma				1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Lumbar, Hemangiosarcoma	1 (17%)			
Lumbar, Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Pancreatic, Fibrosarcoma, Metastatic, Pancreas		1 (11%)		
Pancreatic, Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (7%)	
Pancreatic, Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Lymph Node, Bronchial	(46)	(57)	(57)	(59)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	2 (4%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Lymph Node, Mandibular	(47)	(36)	(45)	(47)
Lymph Node, Mediastinal	(50)	(55)	(57)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Lymph Node, Mesenteric	(59)	(58)	(58)	(56)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Spleen	(60)	(60)	(60)	(60)
Hemangiosarcoma		1 (2%)		
Thymus	(57)	(58)	(59)	(58)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (3%)		1 (2%)
Hemangioma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Thymoma Nos	1 (2%)			
INTEGUMENTARY SYSTEM				
Mammary Gland	(59)	(60)	(60)	(60)
Carcinoma	1 (2%)	2 (3%)		
Squamous Cell Carcinoma, Metastatic, Skin				1 (2%)
Skin	(60)	(60)	(60)	(60)
Fibrosarcoma	1 (2%)	1 (2%)		1 (2%)
Fibrous Histiocytoma	1 (2%)			
Hemangiosarcoma	1 (2%)	1 (2%)		1 (2%)
Hemangiosarcoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma				2 (3%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

MUSCULOSKELETAL SYSTEM

Bone	(60)	(60)	(59)	(60)
Femur, Periosteum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Skeletal Muscle	(4)	(1)	(4)	(3)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (33%)
Carcinoma, Metastatic, Mammary Gland		1 (100%)		
Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (25%)	

NERVOUS SYSTEM

Brain	(60)	(60)	(60)	(60)
Peripheral Nerve	(3)	(0)	(2)	(1)
Spinal Cord	(4)	(0)	(2)	(1)

RESPIRATORY SYSTEM

Larynx	(60)	(59)	(60)	(60)
Lung	(60)	(60)	(60)	(60)
Alveolar/Bronchiolar Adenoma	1 (2%)	7 (12%)	16 (27%)	8 (13%)
Alveolar/Bronchiolar Adenoma, Multiple		3 (5%)	3 (5%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	2 (3%)	7 (12%)	5 (8%)	7 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple		7 (12%)	6 (10%)	4 (7%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Granulosa-Theca Tumor Malignant, Metastatic, Ovary		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	3 (5%)	3 (5%)		1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Mast Cell Tumor Nos, Metastatic, Uncertain Primary Site				1 (2%)
Nose	(60)	(59)	(60)	(60)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Pleura	(0)	(2)	(0)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (50%)		
Trachea	(60)	(60)	(60)	(60)
SPECIAL SENSES SYSTEM				
Ear	(0)	(0)	(0)	(1)
Eye	(59)	(57)	(59)	(59)
Harderian Gland	(59)	(60)	(60)	(60)
Adenoma	3 (5%)	4 (7%)	6 (10%)	2 (3%)
Carcinoma	4 (7%)			2 (3%)
Zymbal's Gland	(0)	(0)	(0)	(1)
Carcinoma				1 (100%)
URINARY SYSTEM				
Kidney	(60)	(60)	(60)	(60)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)	1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Urinary Bladder	(60)	(60)	(60)	(60)
Hemangioma		1 (2%)		
SYSTEMIC LESIONS				
Multiple Organ	*(60)	*(60)	*(60)	*(60)
Histiocytic Sarcoma	3 (5%)	7 (12%)	2 (3%)	3 (5%)
Lymphoma Malignant	7 (12%)	17 (28%)	20 (33%)	30 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 13:46:36

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	35	50	48	51
Total Primary Neoplasms	66	115	110	106
Total Animals with Benign Neoplasms	25	37	37	36
Total Benign Neoplasms	33	55	58	49
Total Animals with Malignant Neoplasms	25	41	35	45
Total Malignant Neoplasms	32	60	52	57
Total Animals with Metastatic Neoplasms	7	13	5	7
Total Metastatic Neoplasms	8	47	13	15
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant	1			
Total Uncertain Neoplasms	1			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors